EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study

Kailin Chen, Yuyi Li, Xiaoyu Chen, Weichang Zhu, Yuchen Shi, Xu Ye, Cuihong Jiang, Yajun Li, Feng Liu

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-11

DOI: 10.2147/dddt.s610324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Kailin Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Chang…. Hauptthemen laut MEDLINE: Quinolines, Nasopharyngeal Carcinoma, Indoles, Nasopharyngeal Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesNasopharyngeal CarcinomaIndolesNasopharyngeal NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedDrug Resistance, NeoplasmAdultImmunotherapyPlatinumAgedNeoplasm Recurrence, Local

Stichwörter der Autor:innen

PD-1 inhibitoranlotinibimmunotherapy-resistantnasopharyngeal carcinomaplatinum-resistant

Substanzen

QuinolinesanlotinibIndolesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPlatinumPDCD1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, 410013, People's Republic of China.
  • Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People's Republic of China.
  • Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, 410013, People's Republic of China.

Zitieren

APA

Chen, K., Li, Y., Chen, X., Zhu, W., Shi, Y., Ye, X., Jiang, C., Li, Y., & Liu, F. (2026). Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s610324

Vancouver

Chen K, Li Y, Chen X, Zhu W, Shi Y, Ye X, et al. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s610324

BibTeX
@article{Chen2026,
  author = {Chen, Kailin and Li, Yuyi and Chen, Xiaoyu and Zhu, Weichang and Shi, Yuchen and Ye, Xu and Jiang, Cuihong and Li, Yajun and Liu, Feng},
  title = {Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/dddt.s610324}
}
Kostenlos starten →